Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOEBUS trial of oral pooled fecal microbiotherapy after allogeneic hematopoietic cell transplantation
NL-OMON59901Phase 2Recruiting
- Sponsor
- MaaT Pharma
- Start
- Oct 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hematopoietic malignancies comparing MaaT033 with Placebo (2 arms). Primary endpoint: Overall survival at 12 months. Started Oct 2024; status: recruiting.
02
Drugs
MaaT-033
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON59901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59901.